Overview
Acquired storage pool deficiency (ASPD) in platelets refers to a condition where there is a reduction in specific granule contents, such as dense granules or alpha granules, leading to impaired platelet function despite normal platelet count. This condition can result from various underlying diseases or treatments and affects hemostatic processes 1.Diagnosis
Clinical Presentation: Bleeding diathesis, particularly mucocutaneous bleeding, petechiae, and prolonged bleeding times 1.
Laboratory Tests: Platelet aggregation studies, flow cytometry to assess granule content, and specific assays for release defects (e.g., epinephrine or ADP-induced dense granule release) 1.
Differential Diagnosis: Exclude congenital platelet disorders and other causes of acquired bleeding disorders through comprehensive hematological evaluation 1.Management
Underlying Cause Treatment: Address and treat the primary condition causing ASPD, such as immune thrombocytopenia (ITP), myelodysplastic syndromes, or medications like aspirin 1.
Prophylactic Measures: Use prophylactic platelet transfusions for high-risk bleeding situations 1.
Factor Support: Consider supplementation with specific coagulation factors if indicated by clinical bleeding severity 1.Special Populations
Pregnancy: Limited specific guidance; management focuses on treating underlying causes and managing bleeding risks with close monitoring 1.
Pediatrics: Similar diagnostic and management approaches as adults, with emphasis on minimizing exposure to potentially harmful treatments 1.
Elderly: Increased vigilance for bleeding complications; tailored management based on comorbidities and functional status 1.
Comorbidities: Tailor treatment considering interactions with existing conditions; careful monitoring for adverse effects of therapies 1.Key Recommendations
Identify and Treat Underlying Cause: Prioritize addressing the primary condition leading to ASPD to potentially reverse storage pool deficiency (Evidence: Expert opinion) 1.
Utilize Specific Laboratory Tests for Diagnosis: Employ platelet aggregation studies and flow cytometry to confirm ASPD (Evidence: Moderate) 1.
Monitor and Manage Bleeding Risk: Implement prophylactic measures and factor support as needed based on clinical bleeding severity (Evidence: Moderate) 1.References
1 Schallmoser K, Henschler R, Gabriel C, Koh MBC, Burnouf T. Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion. Trends in biotechnology 2020. link